Progress of long-acting interferon in Philadelphia chromosome-negative myloproliferative neoplasms / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 628-630, 2023.
Article
Dans Zh
| WPRIM
| ID: wpr-1017364
Responsable en Bibliothèque :
WPRO
ABSTRACT
Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) is a group of chronic hematological tumors caused by clonal proliferation of hematopoietic stem cells, and hydroxyurea is the traditional first-line chemotherapy drug for it. In recent years, pegylated interferon has shown great advantages in the clinical treatment of MPN, and it has become the first-line preferred therapeutic regimen for special populations, especially for young patients and pregnant women.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Journal of Leukemia & Lymphoma
Année:
2023
Type:
Article